Pivagabine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pivagabine
Accession Number
DB12951
Type
Small Molecule
Groups
Investigational
Description

Pivagabine has been used in trials studying the treatment of Stress and Anxiety.

Structure
Thumb
Synonyms
Not Available
External IDs
CXB-722 / CXB722
Categories
UNII
C53SV0WO4V
CAS number
69542-93-4
Weight
Average: 187.239
Monoisotopic: 187.120843411
Chemical Formula
C9H17NO3
InChI Key
SRPNQDXRVRCTNK-UHFFFAOYSA-N
InChI
InChI=1S/C9H17NO3/c1-9(2,3)8(13)10-6-4-5-7(11)12/h4-6H2,1-3H3,(H,10,13)(H,11,12)
IUPAC Name
4-[(1-hydroxy-2,2-dimethylpropylidene)amino]butanoic acid
SMILES
CC(C)(C)C(O)=NCCCC(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmikacinThe risk or severity of adverse effects can be increased when Pivagabine is combined with Amikacin.Approved, Investigational, Vet Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pivagabine.Approved
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Pivagabine is combined with Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pivagabine.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Pivagabine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pivagabine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pivagabine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pivagabine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Pivagabine.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Pivagabine is combined with Clindamycin.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pivagabine.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pivagabine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Cyclosporine.Approved, Investigational, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Desvenlafaxine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pivagabine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pivagabine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pivagabine.Approved, Investigational
DotarizineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Dotarizine.Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.Approved, Vet Approved
EperisoneThe risk or severity of adverse effects can be increased when Pivagabine is combined with Eperisone.Approved, Investigational
EthanolPivagabine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pivagabine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pivagabine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pivagabine.Approved, Illicit, Investigational, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pivagabine.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Fluoxetine.Approved, Vet Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pivagabine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pivagabine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Fluvoxamine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pivagabine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pivagabine.Approved, Investigational
HydrocodonePivagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pivagabine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pivagabine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pivagabine.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pivagabine.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Pivagabine is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Pivagabine is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Pivagabine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Pivagabine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Pivagabine is combined with Magnesium Trisilicate.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pivagabine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pivagabine.Approved
NeomycinThe risk or severity of adverse effects can be increased when Pivagabine is combined with Neomycin.Approved, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pivagabine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pivagabine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pivagabine.Approved, Investigational, Vet Approved
ParomomycinThe risk or severity of adverse effects can be increased when Pivagabine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Pivagabine.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pivagabine.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Pivagabine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PramipexolePivagabine may increase the sedative activities of Pramipexole.Approved, Investigational
PregabalinThe therapeutic efficacy of Pivagabine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pivagabine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pivagabine.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pivagabine is combined with Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pivagabine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Pivagabine is combined with Rizatriptan.Approved
RopinirolePivagabine may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pivagabine.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Pivagabine is combined with Sumatriptan.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pivagabine.Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pivagabine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pivagabine.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Pivagabine is combined with Trimethadione.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pivagabine.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Pivagabine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Pivagabine is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pivagabine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Vinpocetine.Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pivagabine.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Pivagabine is combined with Zolmitriptan.Approved, Investigational
ZolpidemPivagabine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pivagabine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
68888
PubChem Substance
347829093
ChemSpider
62118
ChEBI
134834
ChEMBL
CHEMBL1870796
Wikipedia
Pivagabine
ATC Codes
N06AX15 — Pivagabine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentFeeling Anxious / Stress1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.18 mg/mLALOGPS
logP0.93ALOGPS
logP0.59ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)4.13ChemAxon
pKa (Strongest Basic)6.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area69.89 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity49.13 m3·mol-1ChemAxon
Polarizability20.66 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Branched fatty acids / Secondary carboxylic acid amides / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Gamma amino acid or derivatives / Branched fatty acid / Fatty acyl / Fatty acid / Carboxamide group / Secondary carboxylic acid amide / Carboxylic acid / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:33 / Updated on August 02, 2018 06:45